Sorafenib, the only FDA‐approved first‐line treatment for advanced HCC, is a multi‐target kinase inhibitor for Raf kinases, vascular endothelial growth factor, and platelet‐derived growth factor receptors, and improves survival with a median OS rate of 6.5 months compared to the placebo group (Cheng et al, 2009). Here, VEGFA is linked to hepatocellular carcinoma.